Neurotech International Ltd

Neurotech International Ltd is a dynamic biopharmaceutical company dedicated to advancing clinical-stage research, particularly in the realm of pediatric neurological disorders. With a strong focus on innovation and improving patient outcomes, Neurotech International Ltd is committed to developing cutting-edge therapies and solutions. The company operates from its primary address at 145 Stirling Highway, Suite 5 CPC, Nedlands, WA 6009, AU, and also maintains a presence at Malta Life Sciences Park, Block LS3, San Gwann, San Gwann SGN3000, MT.

Neurotech International Ltd has made significant strides in addressing conditions such as Autism Spectrum Disorder (ASD), with successful Phase I/II clinical trials demonstrating the safety and efficacy of NTI164. Building on this momentum, Neurotech International Ltd is actively engaged in a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD. Furthermore, the company is expanding its research efforts to include Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), as well as Cerebral Palsy.

In addition to its groundbreaking research initiatives, Neurotech International Ltd is also commercializing Mente, an innovative home therapy that has been clinically proven to enhance engagement and promote relaxation in autistic children with elevated Delta band brain activity. Neurotech International Ltd continues to solidify its position as a leader in the biopharmaceutical industry, driven by a passion for transforming the lives of children with neurological disorders. We invite the management of Neurotech International Ltd to create a customized and exclusive company showcase and product listing on our platform to further enhance their visibility and commercial opportunities.